Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry

Thomas Hueso^{1

2}, Justin Cagnat¹, Kaïssa Ouali¹, Mathilde Haberstich¹, Benoît Henry³, Alina Danu², Camille Bigenwald², Mansouria Merad⁴, Sabine Messayke⁵, Ariane Laparra¹, Madona Sakkal¹, Cristina Smolenschi¹, Antoine Hollebecque¹, Anas Gazzah¹, Capucine Baldini¹, Rastislav Bahleda¹, Benjamin Besse^{6

7}, Charlotte Rigaud⁸, Véronique Minard-Colin^{8

7}, Vincent Ribrag^{1

2}, Salim Laghouati⁵, Elisabeth Chachaty⁹, Fabrice Barlesi^{6

7}, Aurélien Marabelle^{1

7}, Olivier Lambotte^{10

7}, Christophe Massard^{1

7}, Jean-Marie Michot^{1

2}

Affiliations

¹ Early Drug Development Department, Gustave Roussy, F-94805 Villejuif, France.
² Department of Clinical Hematology, Gustave Roussy, F-94805 Villejuif, France.
³ Department of Infectious Disease, Kremlin Bicêtre Hospital (AP-HP), F-94275 Kremlin-Bicêtre, France.
⁴ Department of Medical Emergency, Gustave Roussy, F-94805 Villejuif, France.
⁵ Pharmacovigilance Unit, Clinical Research Direction, Gustave Roussy, F-94805 Villejuif, France.
⁶ Department of Medical Oncology, Gustave Roussy, F-94805 Villejuif, France.
⁷ Paris-Saclay University.
⁸ Department of Pediatric Cancer, Gustave Roussy, F-94805 Villejuif, France.
⁹ Department of Microbiology, Gustave Roussy, F-94805 Villejuif, France.
¹⁰ Department of Internal Medicine and Clinical Immunology, Kremlin-Bicêtre Hospital (AP-HP), UMR1184 IMVA-HB, IDMIT, CEA, INSERM, le Kremlin-Bicêtre, France.

PMID: 40165410
DOI: 10.1093/cid/ciaf164

Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry

Thomas Hueso et al. Clin Infect Dis. 2025.

. 2025 Apr 1:ciaf164.

doi: 10.1093/cid/ciaf164. Online ahead of print.

Authors

Affiliations

¹ Early Drug Development Department, Gustave Roussy, F-94805 Villejuif, France.
² Department of Clinical Hematology, Gustave Roussy, F-94805 Villejuif, France.
³ Department of Infectious Disease, Kremlin Bicêtre Hospital (AP-HP), F-94275 Kremlin-Bicêtre, France.
⁴ Department of Medical Emergency, Gustave Roussy, F-94805 Villejuif, France.
⁵ Pharmacovigilance Unit, Clinical Research Direction, Gustave Roussy, F-94805 Villejuif, France.
⁶ Department of Medical Oncology, Gustave Roussy, F-94805 Villejuif, France.
⁷ Paris-Saclay University.
⁸ Department of Pediatric Cancer, Gustave Roussy, F-94805 Villejuif, France.
⁹ Department of Microbiology, Gustave Roussy, F-94805 Villejuif, France.
¹⁰ Department of Internal Medicine and Clinical Immunology, Kremlin-Bicêtre Hospital (AP-HP), UMR1184 IMVA-HB, IDMIT, CEA, INSERM, le Kremlin-Bicêtre, France.

PMID: 40165410
DOI: 10.1093/cid/ciaf164

Abstract

We investigated infectious complications and the associated risk factors in 181 patients undergoing T-cell engagers for malignancies. Infections were primarily observed in patients with hematological diseases or heavily pre-treated. Mortality due to infectious complications was 2.8%. Concomitant medications with corticosteroids or tocilizumab did not significantly impact the incidence of infections.

Keywords: BCMA; Bispecific antibodies; CD20; DLL3; Infections; T-cell engagers.

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

PubMed Disclaimer

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry

Affiliations

Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry

Authors

Affiliations

Abstract

LinkOut - more resources

Full Text Sources

Research Materials